Chlorpromazine Dosing and Administration for Schizophrenia

Initial Dosing Strategy

The American Psychiatric Association recommends a therapeutic dose equivalent to 600 mg per day for schizophrenia treatment 1

An adequate trial requires 4-6 weeks at sufficient dosage before determining treatment failure 2, 3
First-episode patients should receive maintenance treatment for 1-2 years after the initial episode given relapse risk 2

Chlorpromazine is not the preferred agent for treatment-resistant schizophrenia 1
After failure of at least two adequate antipsychotic trials, treatment resistance should be considered 4, 5
Clozapine should be tried after two failed monotherapy trials with other antipsychotics (at least one should be an atypical agent) 2, 6, 7, 8

The American Academy of Pediatrics and clinical guidelines require adequate informed consent documenting risks and benefits 2, 1
Baseline ECG monitoring is necessary as chlorpromazine causes QTc prolongation and can result in torsades de pointes 1
Regular cardiovascular status assessment throughout treatment is recommended 1
Extrapyramidal symptom monitoring at each visit is necessary 2, 1
Metabolic parameter assessment (weight, glucose, lipids) is required 1

Systematically assess and confirm medication adherence before concluding treatment failure 4, 5
Consider long-acting injectables or blood concentration measurements to verify compliance 6, 7

Never co-administer chlorpromazine with other QT-prolonging medications as this significantly increases risk of cardiac arrhythmias 1
The American Society of Clinical Oncology notes chlorpromazine is more likely to cause hypotension than some other antipsychotics (NNH 7) 1
Extrapyramidal symptoms increase dose-dependently, and doses above 800 mg/day cause substantially more movement disorders 2, 1

Antiparkinsonian agents may be considered for extrapyramidal side effects 2
Antipsychotic monotherapy should be the goal, as polypharmacy increases side effects and healthcare costs 6, 7, 8